BACKGROUND AND OBJECTIVE: Plus disease is the primary indication for retinopathy of prematurity (ROP) treatment, but in borderline cases ophthalmologists may struggle to judge whether it is present. ROPtool is a semi-automated computer program that objectively assesses plus disease by measuring retinal vascular tortuosity and width. This study determined ROPtool's bedside diagnostic accuracy concurrent with ROP screening. PATIENTS AND METHODS: ROP screening examinations were recorded using Keeler video indirect ophthalmoscopy. A masked operator traced images in ROPtool at the bedside, comparing ROPtool's plus diagnosis to the examiner's clinical judgment. RESULTS: Four hundred sixty-four examinations (129 eyes of 65 infants) were performed. ROPtool's sensitivity, specificity, and area under the receiver operating characteristic curve for plus diagnosis was 71% (CI: 38%-100%), 93% (CI: 89%-98%) and 0.87, and for pre-plus or worse was 68% (CI: 51%-85%), 82% (CI: 77%-86%) and 0.81, respectively. CONCLUSION: ROPtool can provide a real-time second opinion of plus disease at the bedside. Image enhancement technologies may further improve ROPtool's diagnostic accuracy. Copyright 2014, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: Plus disease is the primary indication for retinopathy of prematurity (ROP) treatment, but in borderline cases ophthalmologists may struggle to judge whether it is present. ROPtool is a semi-automated computer program that objectively assesses plus disease by measuring retinal vascular tortuosity and width. This study determined ROPtool's bedside diagnostic accuracy concurrent with ROP screening. PATIENTS AND METHODS: ROP screening examinations were recorded using Keeler video indirect ophthalmoscopy. A masked operator traced images in ROPtool at the bedside, comparing ROPtool's plus diagnosis to the examiner's clinical judgment. RESULTS: Four hundred sixty-four examinations (129 eyes of 65 infants) were performed. ROPtool's sensitivity, specificity, and area under the receiver operating characteristic curve for plus diagnosis was 71% (CI: 38%-100%), 93% (CI: 89%-98%) and 0.87, and for pre-plus or worse was 68% (CI: 51%-85%), 82% (CI: 77%-86%) and 0.81, respectively. CONCLUSION: ROPtool can provide a real-time second opinion of plus disease at the bedside. Image enhancement technologies may further improve ROPtool's diagnostic accuracy. Copyright 2014, SLACK Incorporated.
Authors: Grace M Richter; Steven L Williams; Justin Starren; John T Flynn; Michael F Chiang Journal: Surv Ophthalmol Date: 2009-08-08 Impact factor: 6.048
Authors: J Peter Campbell; Esra Ataer-Cansizoglu; Veronica Bolon-Canedo; Alican Bozkurt; Deniz Erdogmus; Jayashree Kalpathy-Cramer; Samir N Patel; James D Reynolds; Jason Horowitz; Kelly Hutcheson; Michael Shapiro; Michael X Repka; Phillip Ferrone; Kimberly Drenser; Maria Ana Martinez-Castellanos; Susan Ostmo; Karyn Jonas; R V Paul Chan; Michael F Chiang Journal: JAMA Ophthalmol Date: 2016-06-01 Impact factor: 7.389
Authors: Marguerite C Weinert; David K Wallace; Sharon F Freedman; J Wayne Riggins; Keith J Gallaher; S Grace Prakalapakorn Journal: J AAPOS Date: 2020-03-27 Impact factor: 1.220
Authors: Sasapin G Prakalapakorn; Laura A Vickers; Rolando Estrada; Sharon F Freedman; Carlo Tomasi; Sina Farsiu; David K Wallace Journal: Open Ophthalmol J Date: 2017-06-29